Sandoz fires back in Zarxio suit

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed an opposition brief to a motion by Amgen Inc. (NASDAQ:AMGN) seeking a preliminary injunction that would prevent Sandoz from marketing Zarxio ( EP2006), a biosimilar of Amgen's Neupogen filgrastim methionyl human G-CSF.

Zarxio's earliest potential launch date is March 8, but Sandoz has agreed not to launch the biosimilar in the U.S. until the earlier of April 10 or a court ruling in favor of Sandoz. In the latter scenario, Sandoz would provide Amgen five days' notice before launching Zarxio. ...